Search

Introduction: Sickle cell disease is the leading genetic disease in Île-de-France. Stroke is one of its most severe complications. In SS sickle cell children, transcranial Doppler (TDC) is, through the study of average speeds of the skull base arteries, the gold standard for screening and diagnosis of vasculopathy. To our knowledge, in adults with sickle cell disease, no standards have been established for the speed of the arteries at the base of the skull. It therefore seemed useful to us to establish an approach to brain speeds recorded in adults with sickle cell disorders without neurovascular complications., Material and Methods: This was an observational, prospective, monocentric study conducted between February 2017 and June 2017. The main objective of the study was to determine the mean and standard deviation of maximum systolic velocities (MSS) and mean maximum velocities for all arteries recorded during the transcranial Doppler echo. The secondary objectives were to compare the mean maximum systolic velocities in sickle cell adults with those of healthy adults, to compare the mean maximum systolic velocities in sickle cell adults with those of sickle cell children, and to determine whether parameters could influence the speeds recorded at TCD., Results: Forty patients were included between February 1, 2017 and June 30, 2017, with an average age of 39.3 years. The mean maximum velocities recorded were: 78cm/s for the middle cerebral arteries; 59.6cm/s for the internal carotid arteries; 61cm/s for the anterior cerebral arteries; 44cm/s for the posterior cerebral arteries and 55cm/s for the basilar trunk., Discussion: The highest circulatory velocities are found in the middle cerebral arteries. The speeds found in the internal carotid arteries and anterior cerebral arteries are faster than in the vertebrobasilar system. Speeds in sickle cell adults are slower than those described in sickle cell children SS but significantly faster than those found in healthy adults., Conclusion: To our knowledge, this study is the first to evaluate transcranial Doppler circulatory velocities in adult sickle cell patients. This work has limitations due to its small sample size, however, it provides a basis for further studies on transcranial Doppler in sickle cell adults., (Copyright © 2019. Published by Elsevier Masson SAS.)

Introduction: Decisions about treatment prescriptions depend on many factors. For example, the choice of once-daily or multiple administration of an analgesic, an aspect that is not determined by guidelines, depends essentially on medical practice habits, patient preferences, or both. We analyzed this treatment decision for acute back pain in a case-control study., Patients and Methods: A case-control study was conducted in metropolitan France between October and December 2005 among outpatients seeing general practitioners and specialists for acute back pain (cervical, thoracic, lumbar and low back pain). We compared the group treated by a once-daily analgesic (tramadol) with those treated by analgesics (WHO analgesic ladder steps 1 and 2) administered twice daily or more. Patients and physicians were questioned about the different supposed determinants of the treatment choice for acute back pain., Results: Patients for whom physicians prescribed a once-daily analgesic had a history of back pain and previous prescriptions for other analgesics more frequently than the other patients, experienced significantly greater pain and more marked disability. The time to recovery estimated by the physicians was shorter for these patients, as was the time to return to work, estimated by patients. Treatment choice was also guided by the patient's choices: the once-daily analgesic was reserved for patients who prefer to take drugs to prevent pain and prefer a single dose daily., Conclusion: The choice of type of analgesic treatment for acute back pain depends not only on clinical condition (pain and disability), but also on clinical history, the future as envisioned by the physician and the patient's desires. Action to improve treatment choices must integrate these factors, especially as part of an overall education in therapeutics.

Objectives: The aim of this observational study in patients with chronic hepatitis C and treated with interferon alpha-2a was to assess 1) monitoring in everyday practice, 2) the acceptability of treatment and 3) the intensity of fatigue., Methods: Three hundred and fifty four patients were enrolled by physicians in both teaching and general hospitals, or private practice. Before treatment, clinical, epidemiological, and virological data were collected as well as a self-evaluation of fatigue using a visual analogic scale. Clinical follow-up was assessed every 3 months during treatment and 6 months after the end of treatment and included an evaluation of fatigue and the number of workdays missed due to sickness., Results: Two hundred and nineteen men and 135 women, mean age 45 +/- 13, were included. The epidemiological, histological and virological features of this group were similar to those patients usually treated for chronic hepatitis C. Before treatment, the mean measurement of fatigue was 41 on a scale from 0 (perfect form) to 100 (exhausted). Fatigue was unrelated to age, source of infection, biological activity, or histological score. It worsened in patients who stopped interferon after 3 or 6 months, but was stable in patients who continued treatment for 12 months. Fatigue decreased after the end of treatment and was unrelated to treatment response. The need to stop work was strongly related to the intensity of fatigue and the number of workdays missed due to sickness represented nearly two months out of three in 25% of active patients during the first quarter and in 15% of patients thereafter. 61% of patients self-injected interferon (mainly previous drug users) whereas 30% of patients used nurse care throughout treatment., Conclusion: This study not only provides a realistic evaluation of fatigue in patients with chronic hepatitis C, before, during and after treatment, but also highlights its social and economic consequences. It shows the need for further cost-effectiveness studies on new therapeutic strategies using combined treatments.

The authors used a prospective study of 309 great saphenous veins to analyse, by Doppler and ultrasonography, the mechanism of sclerosis following sclerosing injections. These were administered at a maximum of 50mm from the sapheno-femoral junction using a protocol based upon five sessions. It was found possible to establish a close relationship between the quality of results and small calibre. Similarly, recurrence by early repermeation was generally secondary to a sclerosing reaction having caused thrombosis. Other changes were seen during or at the end of treatment, sometimes differing greatly from clinical findings. This type of sclerosing injection therapy provided more than 90% favourable responses to treatment after a follow-up period of 15.7 months. Analysis of other parameters may possibly enable even better definition of the treatment of this condition and its natural history.

Isoflurane and halothane, two anaesthetics agents have been compared. Forty young and healthy patients were divided into two randomly selected group. Each of them was anaesthetized either with isoflurane or with halothane. Anaesthesia was maintained with nitrous-oxide and dextromoramide. During induction, the ventilation was spontaneous. Blood-gas, ventilation rate and tidal-volume were studied before induction, during anaesthesia and at the end of the surgery. Statistical data show a higher PaCO2 and a lower pH with isoflurane. This was increased by dextromoramide. During induction, complications occurred more after than with halothane but the emergence was better.